The Supervisory Board of MorphoSys has appointed Dr Malte Peters as Chief Development Officer. Malte will take up the position on March 1, 2017 and will succeed Dr Arndt Schottelius, who is leaving to pursue other opportunities. He joins MorphoSys from Sandoz, where he serves as Global Head, Clinical Development Biopharmaceuticals.
Malte built his career in early and late-stage clinical development over the last 18 years. Prior to his latest role at Sandoz, he spent 12 years in various managerial positions within Novartis focusing on management of clinical development projects in oncology. Before that, he served in positions as Medical Director at Micromet AG and as Head of Translational Research and Pharmacogenomics at Merck KGaA.
